OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
The Design of SPRINT MIND and SPRINT MIND 2020	2932
Survey on knowledge of Uruguayan neurologist about the FINGER intervention	2453
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory	2249
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances	514
The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis	353
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study	260
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease	241
Neural flexibility as a promising biomarker for Alzheimer’s Disease	236
The Types and Consistency of Participant‐Specified Proxies During SPRINT	213
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	213
Putative Cellular Identity of Dystrophic Neurites in FTLD‐TDP Type C	205
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	200
Investigating the Association Between P2Y12 Receptor, SV2A, and Tau Expression in Postmortem AD and Control Brains Using In Vitro Autoradiography	192
Neuroprotective Potential of Limonene in LPS induced Parkinson’s Disease in Rats	172
Glial and synaptic biomarkers as early indicators of mild cognitive decline	158
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease	154
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	151
Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change	150
Physical Activity, Social Support, and the Health of Dementia Caregivers: A Scoping Review	134
Frontotemporal Dementia & the Criminal Legal System: Care Partner Stories	129
Childhood trauma and cognition status in an elderly sample with a mental disorder	128
SENSE‐Cog Residential Care: A Pilot Cluster Randomized Trial on Hearing and Vision Support for Residents with Dementia in Long‐term Care	127
Who Uses Memory Strategies? Exploring the Influence of Cognitive Reserve on Use of Memory Strategies by Older Adults Referred for Neuropsychological Assessment	126
Reducing Gerontophobia and Improving Cognition: A Study on the Efficacy of Mindfulness‐Based Cognitive Therapy in Older Adults in India	125
Ciclosonide reduces lipid droplet burden in APOE4 astrocytes	122

“CLOVER” Model of Service and Training Development for the Well‐being of People with Dementia in Residential Care Homes of Hong Kong	120
The Dementia Literacy Assessment (DeLA): A Novel Measure of Alzheimer's Disease and Related Disorders Health Literacy in Diverse Populations	117
An interrupted time‐series design experiment of research registry recruitment interventions	112
Pterostilbene Ameliorates Hyperhomocysteinemia‐Induced Cognitive Impairment: Involvement of Mitochondrial Dysfunction, Synaptic Plasticity, and Adult Neurogenesis	111
Herbal Therapeutics in Alzheimer's Disease: Investigating Behavioral and Biochemical Changes in Animal Model	108
“ I know you didn’t want to stay ”: Emergency Department Conversations about Disposition for People Living with Dementia	108
Dementia registry in Guinea: clinical and etiological aspects at the Neurological Department of the Conakry teaching Hospital	107
Simultaneous reduction of amyloid beta and phosphorylated tau for Alzheimer’s Disease with Chemically Optimized Stringed Modifiable Oligonucleotides (COSMOs)	106
The Utility of the WMS‐IV LM Subtest as an Inclusionary Measure in Early AD Trials	105
Impact of icosapent ethyl on CSF NULISA vascular, metabolic, and AD biomarkers in cognitively unimpaired Veterans at risk for dementia	101
Anti‐NMDA Receptor Encephalitis in a Young Adult with Neuropsychiatric and Cognitive Symptoms‐ A Case Study	100
False Negative Twenty‐Nine Montreal Cognitive Assessment Score in Moderately ADL‐Impaired UDS Patients: A Case Series Study of 23 Patients	99
The glymphatic system's role in linking cardiometabolic health to cerebral small vessel disease and frailty in Chilean healthy older adults	99
Natural Language Processing differentiates between Italian individuals with Nonfluent/Agrammatic from Logopenic variants of PPA	99
Cross‐ validation of Free‐Cog with routinely used cognitive and functional tools in Canadian Memory Clinics	96
Neuropsychiatric symptom subtypes associated with Alzheimer's disease and related dementia neuropathologic changes in the National Alzheimer's Coordinating Center neuropathology cohort	96
Neuropsychiatric Symptoms in Comorbid Alzheimer's Disease Neuropathologic Change and Frontotemporal Lobar Degeneration	93
Implementation of AD BBMs: Approach in Memory Clinics in the Netherlands	91
Association of MBI‐C scores with clinical outomes in patients with MCI during a 3‐year follow‐up	90
Genetic Intersections of ADHD and Alzheimer's Disease: A Systematic Review	90
Achieving Dissemination and Implementation Success in Dementia Care: A Consideration of Methodological Strategies	89
Effect of Orexin receptor antagonists for patients with Lewy bodies: Lemborexant do not make worse cognitive function and REM sleep Behavior Disorder in DLB	89
The Impact of Testing Environments on Remote Cognitive Assessments in Alzheimer's Disease	88
Trip‐Based Measures of Naturalistic Driving: Exploring connections to older adult drivers with respect to amyloid‐positive and amyloid‐negative	87
Predicting brain health in older adults through automated language measures	86
Women are less likely to be eligible for AD trials than men.	85
Sensory Healthcare for People with Dementia in Diverse Care Settings	85
Rare Dementia Support Canada: Localizing and mobilizing knowledge to build inclusive supports for families affected by atypical dementias	85
Distinct trajectories of subjective cognitive decline before diagnosis of neurocognitive disorders: Longitudinal modelling over 18 years	84
Cerebellar degeneration and its integrative role in brain networks for social cognition in early‐stage bvFTD	83
Nutritional status and eating disturbances among patients with neurocognitive disorder	83
EMA perspective on Diagnosis of Alzheimer's	83
The Moderating Effect of Perceived Susceptibility and Decision Conflict on the Relationship Between Comorbidities and Quality of Life Among Caregivers of People with Dementia	82
Evaluating the effect of ethnicity and amyloid on gait speed in the Healthy Aging Brain Study‐Health Disparities Study	81
Pulse pressure is associated with Alzheimer's disease pathology and cognitive decline	81
Dementia Dastan: Understanding the Experiences of South Asian Canadians Living with Dementia and their Care Partners	80
Domestic Environment of Multisensory Stimulation based on Snoezelen principles pilot study	80
What is the prevalence of impaired cognitive domains in surgical patients? A systematic review and meta‐analysis	78
Evaluating the impact of delayed auditory feedback in primary progressive apraxia of speech: acoustic, perceptual, and patient reported outcomes	78
Divergent Functional Capacity in Alzheimer's Disease and Frontotemporal Dementia: Insights from the Peruvian Adaptation of the Amsterdam Instrumental Activities of Daily Living Questionnaire	77
The Psychological Impact of Receiving a Biomarker Informed ADRD Diagnosis in a Real‐World Sample: the PARADE Study	76
Exploring Memory Trajectories in Aging: A Longitudinal Study of Superagers and Memory Maintenance	74
Exploring Emotional Well‐Being in Exceptional Aging: Data from the SuperAging Research Initiative	74
Speed of cognitive decline in biomarker stratified SCD subgroups	73
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy	73
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	72
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	71
Automating the verbal paired associates test to assess memory remotely and at scale	71
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	70
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	70

A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	67
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	67
Neuropathology of a patient with AD treated with low doses of verubecestat	66
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	66
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	66
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	65
Whole‐exome sequencing of a Portuguese cohort of early‐onset Alzheimer’s disease implicates X‐linked lysosomal gene GLA	64
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	64
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	63
Human postmortem studies as a driver of biomarker development	63
Widespread transposable element dysregulation in human brains with Alzheimer’s disease	63
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	63
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	61
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	60
Automated word class and person usage metrics as markers of Alzheimer’s and frontotemporal dementia	59
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	59
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	59
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	59
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	58
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	58
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	58
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	58
Anti‐ulcer drug teprenone clinical trial	58
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	58
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	57
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	57
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	57
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	57
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	55
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	55
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	55
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	55
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	54
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	54
Combined effect of prebiotic and probiotic strains restores cognitive impairment via attenuating synaptosis in the hippocampus of mice fed with high fat diet and streptozotocin diabetes‐induced dement	54
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	54
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	53
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	53
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	53
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	53
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	53
Automated lexical analysis of story recall in healthy controls	53
Elderly Role Performance Occupational Therapy	52
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	52
Perceptions of Shared decision making in cognitive impairment of LTC recipients	52
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	51
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	51
Impact of the COVID‐19 Pandemic on Patients with Dementia or Parkinson’s Disease and their Caregivers in Lima, Peru	51
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	50
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	50
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	50
Identification of objective cognitive decline in preclinical Alzheimer’ disease	49
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	49
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	49
Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood‐Brain Barrier Opening and Delivery of a Novel Anti‐Amyloid Re Complex for Memory Improvement in a 3xTg‐Alzheimer’s Disease Mo	49
Microglial‐targeted nSMase2 inhibitor fails to reduce tau spread in the animal model of Alzheimer’s disease	48
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	48
Clinical outcome assessments for LBD trials – Should we borrow?	48
Issue Information	48
Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials	47
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	47
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	47
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	47
Delivery of incretin receptor agonists to the brain	47
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	47
Development of pyroptosis inhibitors for Alzheimer’s disease	47
CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease	47
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	47
	46
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	46
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	46
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	46
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	46
A Comparison of the Prevalence of Diabetes between Aging Rural and Urban Indians.	45
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	45
Relation Between Educational Attainment and Cerebral Small Vessel Disease: the Framingham Heart Study	45
Sex modifies the associations of regional fat with cognitive functioning and AD‐related brain volumes, in Israeli middle‐aged adults at high AD risk	45
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	45
Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case‐control study using Dutch primary care data	45
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	45

Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	45
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	45
Social media responses to the approval of lecanemab in Japan: sentiment analysis	45
Impact of Metabolic Syndrome Longitudinal Changes on Cognitive Health: A 10‐Year Follow‐up Study in Middle‐Aged Adults	44
Additive Impact of Cardiometabolic Multimorbidity and Depression on Cognitive Decline: Findings from Multi‐Regional Cohorts and Generalization from Community to Clinic	44
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	44
Improvement of Knowledge and Research Attitudes on Preclinical Alzheimer’s Disease Trials through Community‐based Education Among Underrepresented Korean, Filipino, and Hispanic Americans	44
Engaging and Recruiting Latino‐led Community Organizations to Build Workforce Capacity in AD/Brain Health Prevention Research	43
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	43
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	43
Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia	42
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	42
The potential protective benefit of personality on subjective cognitive decline related worry: Results from the Canadian Longitudinal Study on Aging (CLSA)	41
Applying novel EMBRACE technological solutions to measure and optimize brain response to exercise.	41
Bibliographic Analysis of Aging Anxiety and Lifestyle	41
How well is Brazil prepared for a disease‐modifying Alzheimer’s treatment?	41
Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research	41
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	41
Risk knowledge and risk perception of MCI patients and their caregivers in predictive diagnosis of AD: Findings from the PreDADQoL study	40
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	40
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	40
Associations between blood‐based biomarkers and other outcomes related to Alzheimer’s disease	40
APOE loss‐of‐function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology	40
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	40
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	40
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	40
Racial differences in white matter hyperintensity load in aging, MCI, and AD	40
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	40
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	40
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	39
Is QEEG an effective biomarker in predicting cognitive decline?	39
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	39
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	39
Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study	39
	39
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	39
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	39
Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective	39
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	39
Association of the learning ratio with AD biomarkers after application of actuarial diagnostic criteria to ADNI cognitively normal participants	38
The role of clusterin and the variant rs11136000_T throughout the spectrum of Alzheimer’s disease	38
The Advanced Therapeutics for Alzheimer’s Disease Review Board: A Multidisciplinary Model to Facilitate Safe Access to Lecenemab across the Sutter Health System	38
Developing a preference‐based quality of life for people living with dementia in Vietnam	38
A cluster randomized trial: Exploratory quantitative analysis comparing resident outcomes for two approaches to promote non‐pharmacological, resident‐centered dementia care in nursing homes	38
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	38
Issue Information	38
Comparison of histological delineation of the entorhinal, perirhinal, ectorhinal, and parahippocampal cortices by different neuroanatomy laboratories	38
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	38
Movement with Dementia: A feasibility study of a resource to support the personalisation of therapeutic exercise programmes for people living with dementia	37
Motor alterations associated with cognitive impairment in a third‐level hospital	37
Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model	37
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	37
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline	37
Description of the Gut Microbiome Composition in Puerto Ricans with Alzheimer’s Disease Compared to Healthy Controls	37
Dynamic disease‐associated gene regulatory transitions unmask genetic risk associated neurodegenerative cell states	36
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	36
Proteomics identification of novel proteins dysregulated in Alzheimer’s Disease with potential as blood‐based biomarkers and related to Amyloid‐Beta Plaques	36
Sex and APOE differences in Alzheimer’s Disease‐On‐Ramp risk factor profiles: Are all risk factors for Alzheimer’s Disease created equal?	36
Testamentary Capacity Assessment Tool (TCAT): An update report	36
A passive, neural correlate of verbal fluency in Mild Cognitive Impairment using Fastball neurocognitive assessment	36
The role of impaired oxidative base lesion repair in Alzheimer’s disease	35
Expanded bile acid annotations linked to diet and AD biomarkers	35
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	35
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	35
Prevalence of dementia diagnoses in a safety net health system	35
Associations between imaging biomarkers and sleep quality in the U.S. POINTER study baseline cohort	35
Complement receptor 1 length polymorphism impacts glial functions relevant to Alzheimer’s disease	35
Production and characterization of human tau protein with site‐specific phosphorylation utilizing E. coli with an expanded genetic code	35
Interaction between polymorphisms in MBP and EIF2B5 genes is significantly associated with Alzheimer’s disease	35
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	35
Anosognosia and caregiver distress independently identify subjects at high risk of developing dementia of Alzheimer’s type	35
Targeted Multiplexed MALDI MS Platform Enables Detection of Novel Pathogenic Forms of Tau, Amyloid Beta and Alpha Synuclein	35
Neurobiological correlates of grey matter morphometry changes in preclinical Alzheimer’s disease	35
Increased fibrin deposition in the brains of individuals with Down syndrome and Alzheimer’s disease	35
Persistent DNA damage response drives cGAS‐STING mediated neuroinflammation in a mouse model of tauopathy	35
Multiple pathological mechanisms of Bin1 for tau aggregation and propagation	35
Whole blood DNA methylation profiles of Alzheimer’s disease differ across ancestrally diverse populations	35
Retinal Examination in Neurodegenerative Diseases of the Brain	35
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	35
Integrative Analysis of Genetic Network and Brain Imaging using Generative Models for Alzheimer’s Disease Prediction	35
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	34
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	34
Cardiorespiratory fitness is an important marker of cognitive performance in older Latin Americans	34
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	34
Family care partners experiences of delirium in caring for a person with dementia: Qualitative descriptive study	34
Aberrant resting‐state functional connectivity of the default‐mode network relates to cognitive decline in the earliest Alzheimer’s continuum	34
Contrast of Early Phase Amyloid PET	34
CSF biomarkers trajectories across the AD spectrum reveal the temporal dynamics of amyloid and tau	34
The Effect of COVID‐19 Lockdown on Dementia Caregivers in the U.S.	33
Myelin water imaging with clinically feasible scan time: the accelerated BMC‐mcDESPOT (aBMC‐mcDESPOT) method	33
Synapse loss in early‐ and late‐onset Alzheimer’s Disease assessed by 18F‐SynVest‐1	33
Intracranial atherosclerosis is linked to lower volume in the posterior portion of the hippocampus	33
Deep learning‐based estimation of future brain atrophy using baseline MRI and PET	33
Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer’s disease in a diverse cohort	33
Cost‐effectiveness analysis of the multimodal intervention for dementia prevention: post‐hoc sub‐group analyses of the J‐MINT	33